Sanofi (SNYNF) Operating Income Growth (1y) (2010 - 2026)
Sanofi (SNYNF) Operating Income Growth (1y) (2010 - 2026) Analysis & Trends
Peer Comparison
| # |
Company |
Market Cap |
Enterprise Value |
Gross Profit (Qtr) |
Op. Inc Growth (1y) (Qtr) |
| 1 |
Gsk |
96,436,181.12 Bn |
96,436,176.16 Bn |
7.76 Bn |
10.76% |
| 2 |
Eli Lilly |
1,017.30 Bn |
1,012.01 Bn |
16.22 Bn |
80.35% |
| 3 |
Johnson & Johnson |
579.61 Bn |
557.55 Bn |
15.96 Bn |
2.93% |
| 4 |
AbbVie |
402.30 Bn |
392.96 Bn |
10.78 Bn |
6.88% |
| 5 |
Merck |
294.24 Bn |
288.59 Bn |
12.09 Bn |
-411.15% |
| 6 |
Amgen |
191.82 Bn |
179.78 Bn |
5.87 Bn |
126.32% |
| 7 |
Gilead Sciences |
155.93 Bn |
148.21 Bn |
5.52 Bn |
15.60% |
| 8 |
Pfizer |
149.05 Bn |
136.28 Bn |
-1.21 Bn |
-0.98% |
| 9 |
Bristol Myers Squibb |
116.33 Bn |
105.88 Bn |
8.07 Bn |
-193.55% |
| 10 |
Sanofi |
- |
- |
9.49 Bn |
3.31% |
| Date | Value |
|---|
| Mar 31, 2026 |
3.31% |
| Dec 31, 2025 |
-1,011.95% |
| Sep 30, 2025 |
122.04% |
| Jun 30, 2025 |
1.13% |
| Mar 31, 2025 |
79.00% |
| Dec 31, 2024 |
-91.82% |
| Sep 30, 2024 |
11.19% |
| Jun 30, 2024 |
-18.50% |
| Mar 31, 2024 |
-49.21% |
| Dec 31, 2023 |
78.89% |
| Sep 30, 2023 |
27.27% |
| Jun 30, 2023 |
32.48% |
| Mar 31, 2023 |
-1.73% |
| Dec 31, 2022 |
148.25% |
| Sep 30, 2022 |
-23.19% |
| Jun 30, 2022 |
-17.55% |
| Mar 31, 2022 |
8.42% |
| Dec 31, 2021 |
-5.15% |
| Sep 30, 2021 |
21.28% |
| Jun 30, 2021 |
-79.13% |
